GENOME ANNOUNCEMENT {#s1}
===================

Gill disease is an important disease of cultured fish worldwide. We sequenced the Chryseobacterium species in this report based on their prior association with fish and gill disease ([@B1][@B2][@B4]). The purpose is to facilitate investigation of the etiologic agents of gill disease in the United States.

Chryseobacterium spp. type strains were obtained from the Leibniz Institute DSMZ--German Collection of Microorganisms and Cell Cultures (DSM). DNA was extracted using a MO BIO Ultra Clean microbial DNA isolation kit (MO BIO Laboratories, Inc., Carlsbad, CA, USA) according to the manufacturer's recommendations. Whole-genome sequencing (WGS) was performed using v3 chemistry with paired-end 2× 300-bp reads on the MiSeq platform (Illumina, San Diego, CA, USA). Sequencing libraries were prepared according to the Illumina Nextera XT sample preparation guide.

WGS data were imported into CLC Genomics Workbench, and a *de novo* assembly was performed using default CLC Genomics Workbench version 8.0 assembly parameters (Qiagen, Valencia, CA, USA). Contigs of less than 300 bp were removed from analysis. The genomes were annotated using the NCBI Prokaryotic Genomes Annotation Pipeline (PGAP V4) (<https://www.ncbi.nlm.nih.gov/genome/annotation_prok/>). WGS assembly data are shown in [Table 1](#tab1){ref-type="table"}.

###### 

Summary of analyses of type strains associated with fish gill disease

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sample no.   Strain      Species                      No. of\   Assembly\   G+C\       Coverage\   Total no.\   Total no.\                                      No. of\   No. of\   GenBank\
                                                        contigs   size (bp)   content\   (×)         of genes     of CDS[^*a*^](#ngtab1.1){ref-type="table-fn"}   coding\   RNA\      accession no.
                                                                              (%)                                                                                 CDS       genes     
  ------------ ----------- ---------------------------- --------- ----------- ---------- ----------- ------------ ----------------------------------------------- --------- --------- -------------------------------------------------------------------
  CVM 43419    DSM 21068   Chryseobacterium piscicola   43        3,444,097   33.82      118         3,110        3,059                                           3,025     51        [MUGO00000000](https://www.ncbi.nlm.nih.gov/nuccore/MUGO00000000)

  CVM 43418    DSM 17126   Chryseobacterium shigense    42        4,895,125   37.47      81          4,424        4,353                                           4,309     71        [MUGP00000000](https://www.ncbi.nlm.nih.gov/nuccore/MUGP00000000)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CDS, coding DNA sequences.

The publicly available resistance gene database ResFinder was used for identification of antimicrobial resistance genes, with a 90% sequence identity and 60% length minimum used to identify resistance genes ([@B5]). None of the sequenced isolates carried acquired resistance genes.

Accession number(s). {#s1.1}
--------------------

These draft genomes have been deposited in GenBank under the accession no. indicated in [Table 1](#tab1){ref-type="table"}.
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